Y-mAbs Therapeutics Inc. (YMAB)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 6.02 |
Market Cap | 270.08M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.54 |
PE Ratio (ttm) | -11.17 |
Forward PE | n/a |
Analyst | Buy |
Ask | 6.08 |
Volume | 293,131 |
Avg. Volume (20D) | 376,861 |
Open | 6.01 |
Previous Close | 6.03 |
Day's Range | 5.93 - 6.21 |
52-Week Range | 5.71 - 20.90 |
Beta | undefined |
About YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...
Analyst Forecast
According to 10 analyst ratings, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 281.43% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News

2 weeks ago · seekingalpha.com
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical TrialsYMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for ass...